Right people, right time

A letter from LJI Board Chair Tom Tullie, MBA
Portrait photo of LJI Board Chair Tom Tullie, MBA. He is wearing a sports coat and standing outside.
LJI Board Chair Tom Tullie, MBA

As I step into the role of Chair of the La Jolla Institute for Immunology (LJI) Board of Directors, I couldn’t be more excited for the opportunity to work alongside this team of scientific leaders. Every year, LJI scientists rank among the top 1 percent of highly cited researchers in immunology. Their contributions place them among the very best in the world.

LJI brings together the top scientists, at the perfect time, with cutting-edge technology to deliver scientific breakthroughs in immunology. I genuinely believe that within my lifetime, we will have the ability to eradicate many of the diseases that have plagued humanity.

While LJI may be smaller than many leading institutions, I see this as one of its greatest strengths. As an entrepreneur, I’ve found that a certain scrappiness often separates those who succeed from those who don’t. LJI’s size and scientific acumen give it an agility that larger organizations simply can’t match. Its researchers can move faster, adapt more quickly, and find solutions that evade others.

Scientists at LJI proved that a vaccine could stop the spread of COVID-19, and they developed their own highly accurate COVID-19 screening method early in the pandemic. LJI researchers have also responded rapidly to the recent spread of Ebola virus, mpox, and hantavirus. These advances in infectious disease research laid the foundation we need to develop the next generation of vaccines. If we can build on this momentum, I believe vaccine breakthroughs have the potential to improve the lives of more people than almost any other medical innovation.

In addition to our vaccine work, focus on infectious disease, and concentration on sex-based differences in the immune system, LJI performs world-class cancer research. These studies bring me hope for the future of medicine. For example, LJI scientists have uncovered how the immune system’s T cells target pediatric brain tumors, an important step toward helping identify which young patients could benefit from cancer-fighting immunotherapies.

But great science requires sustained support. That’s why I’m also chairing the new Campaign for LJI. Through this effort, we aim to raise $55 million in philanthropic support, and we are already well on our way.

When I give, I look at the impact of every dollar. I want to support scientific endeavors that create meaningful change. LJI is working toward something extraordinary: a world of Life Without Disease®. That’s a mission I am proud to support.

Sincerely,

Tom Tullie, MBA
Chair of the Board, La Jolla Institute for Immunology
Chair, Campaign for La Jolla Institute for Immunology